Affymetrix Announces Research Collaboration With Centre for Proteomic and Genomic Research (CPGR) in South Africa
November 20 2012 - 7:00AM
Business Wire
Affymetrix, Inc. (NASDAQ: AFFX) today announced a research and
service collaboration with the Centre for Proteomic and Genomic
Research (CPGR) in South Africa. CPGR will provide gene expression
and Axiom genotyping services to African researchers using
GeneTitan® Multi-Channel (MC) Instrument. The Affymetrix and CPGR
partnership aims to enable high-throughput genomics research and
personalized medicine projects across Africa.
The CPGR is a nonprofit organization funded by the Technology
Innovation Agency (TIA), which is based on an initiative by the
Department of Science and Technology (DST) whose goal is to develop
the bio-economy in South Africa. According to Dr Reinhard Hiller,
Managing Director of the CPGR, “The high throughput capability of
GeneTitan® MC Instrument combined with customizable Axiom®
Genotyping Arrays is ideal for meeting the needs of scientists in
Africa whose research projects range from small pilot to
large-scale discovery to focused validation studies. GeneTitan® MC
Instrument expands our genomics service capabilities and will
further enable CPGR to support cutting-edge translational research
in Africa. Further, it allows discovery and validation of
disease-related biomarkers economically – even when searching for
very rare genetic variants. We expect to progress personalized
medicine studies that aim to discover genetic markers specific in
the African population for better diagnosis and drug
treatment.”
It is a well-known fact that genetic variability of African
populations is far greater than in other regions in the world. This
is particularly important when considering that African populations
are underrepresented in most studies on hereditary diseases and
pharmacogenomics. Applying these types of genomic discoveries to
clinical practices has the potential to change health and wellness
of African populations.
“We are excited to partner with CPGR and see this as a
significant opportunity to ensure that African populations are
represented in genomics research studies leading to personalized
therapies. Affymetrix is leading the way in population optimized
genotyping analysis and was the first to create a genotyping array
with content derived specifically from African populations,” said
Chris Barbazette, VP of Commercial Operations, International
Markets at Affymetrix.
Products mentioned in this release are for research use only.
Not for diagnostic procedures.
PLEASE NOTE: Affymetrix®, the Affymetrix logo, Axiom®,
GeneChip®, GeneTitan®, QuantiGene®, SensationPlusTM, and all other
trademarks are the property of Affymetrix, Inc. All other
trademarks are the property of their respective owners.
About the CPGR
The CPGR is a specialist not-for-profit contract research
organization established in South Africa through funding by the
Technology Innovation Agency (TIA) to provide support and services
to the life science and biotech community. It is based on an
initiative by the Department of Science and Technology (DST) to
boost the development of a bio-economy in South Africa. The CPGR
combines state-of-the-art information rich genomic and proteomic
('omics') technologies with bio-computational pipelines, and
biological models, to create unique solutions in the human health
and the agri-biotech sectors. Please visit www.cpgr.org.za for more
information or contact Dr Reinhard Hiller at
reinhard.hiller@cpgr.org.za.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies, as well as
leading academic, government, and nonprofit research institutes.
More than 26,000 peer-reviewed papers have been published citing
the technologies. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Santa Clara, San Diego,
Cleveland, Ohio, Singapore, and Austria. The company has about
1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024